

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 August 28; 23(32): 5829-6008



### EDITORIAL

- 5829 Role of tissue microenvironment resident adipocytes in colon cancer  
*Tabuso M, Homer-Vanniasinkam S, Adya R, Arasaradnam RP*

### REVIEW

- 5836 Ophthalmic manifestations in patients with inflammatory bowel disease: A review  
*Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C*
- 5849 Laparoscopic appendectomy for acute appendicitis: How to discourage surgeons using inadequate therapy  
*Hori T, Machimoto T, Kadokawa Y, Hata T, Ito T, Kato S, Yasukawa D, Aisu Y, Kimura Y, Sasaki M, Takamatsu Y, Kitano T, Hisamori S, Yoshimura T*
- 5860 Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications  
*Niu ZS, Niu XJ, Wang WH*

### MINIREVIEWS

- 5875 Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions  
*Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D'Andrea MR*

### ORIGINAL ARTICLE

#### Basic Study

- 5887 Comparison between tocotrienol and omeprazole on gastric growth factors in stress-exposed rats  
*Nur Azlina MF, Qodriyah HMS, Chua KH, Kamisah Y*
- 5895 (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon- $\lambda$ 1 production and inhibits hepatitis C virus replication in hepatocytes  
*Wang YZ, Li JL, Wang X, Zhang T, Ho WZ*
- 5904 Effects and mechanism of adenovirus-mediated phosphatase and tension homologue deleted on chromosome ten gene on collagen deposition in rat liver fibrosis  
*Xie SR, An JY, Zheng LB, Huo XX, Guo J, Shih D, Zhang XL*

#### Retrospective Study

- 5913 Integrating *TYMS*, *KRAS* and *BRAF* testing in patients with metastatic colorectal cancer  
*Ntavatzikos A, Spathis A, Patapis P, Machairas N, Peros G, Konstantoudakis S, Leventakou D, Panayiotides IG, Karakitsos P, Koumariou A*

**Clinical Trials Study**

- 5925 Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies

*Hedenström P, Nilsson B, Demir A, Andersson C, Enlund F, Nilsson O, Sadik R*

**Observational Study**

- 5936 Novel predictors for lymph node metastasis in submucosal invasive colorectal carcinoma

*Yim K, Won DD, Lee IK, Oh ST, Jung ES, Lee SH*

- 5945 Changes with aging in gastric biomarkers levels and in biochemical factors associated with *Helicobacter pylori* infection in asymptomatic Chinese population

*Shan JH, Bai XJ, Han LL, Yuan Y, Sun XF*

**Prospective Study**

- 5954 Modified *Helicobacter* test using a new test meal and a <sup>13</sup>C-urea breath test in *Helicobacter pylori* positive and negative dyspepsia patients on proton pump inhibitors

*Tepeš B, Malfertheiner P, Labenz J, Aygen S*

- 5962 Real time endoscopic ultrasound elastography and strain ratio in the diagnosis of solid pancreatic lesions

*Okasha H, Elkholy S, El-Sayed R, Wifi MN, El-Nady M, El-Nabawi W, El-Dayem WA, Radwan MI, Farag A, El-sherif Y, Al-Gemeie E, Salman A, El-Sherbiny M, El-Mazny A, Mahdy RE*

- 5969 Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection

*Xue Y, Zhang LX, Wang L, Li T, Qu YD, Liu F*

**Randomized Controlled Trial**

- 5977 New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial

*Jeong JY, Sohn JH, Baek YH, Cho YK, Kim Y, Kim H*

**Randomized Clinical Trial**

- 5986 Randomized clinical trial comparing fixed-time split dosing and split dosing of oral Picosulfate regimen for bowel preparation

*Jun JH, Han KH, Park JK, Seo HL, Kim YD, Lee SJ, Jun BK, Hwang MS, Park YK, Kim MJ, Cheon GJ*

**META-ANALYSIS**

- 5994 Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease

*Restellini S, Kherad O, Bessissow T, Ménard C, Martel M, Taheri Tanjani M, Lakatos PL, Barkun AN*

**CASE REPORT**

- 6003** Postoperative inflammation as a possible cause of portal vein thrombosis after irreversible electroporation for locally advanced pancreatic cancer

*Su JJ, Su M, Xu K, Wang PF, Yan L, Lu SC, Gu WQ, Chen YL*

**LETTERS TO THE EDITOR**

- 6007** Comment on "Efficacy and adverse events of cold *vs* hot polypectomy: A meta-analysis"

*Sun HH, Huang SL, Bai Y*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Mitsushige Sugimoto, MD, PhD, Associate Professor, Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Otsu 520-2192, Japan

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

**I-IX** Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Fen-Fen Zhang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*  
**Responsible Science Editor:** *Yuan Qi*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
 ISSN 1007-9327 (print)  
 ISSN 2219-2840 (online)

**LAUNCH DATE**  
 October 1, 1995

**FREQUENCY**  
 Weekly

**EDITORS-IN-CHIEF**  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Yuan Qi, Vice Director  
 Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.fpublishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpoffice@wjgnet.com](mailto:bpoffice@wjgnet.com)  
 Help Desk: <http://www.fpublishing.com/helpdesk>

<http://www.wjgnet.com>

**PUBLICATION DATE**  
 August 28, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.fpublishing.com>

## Observational Study

**Changes with aging in gastric biomarkers levels and in biochemical factors associated with *Helicobacter pylori* infection in asymptomatic Chinese population**

Jin-Hua Shan, Xiao-Juan Bai, Lu-Lu Han, Yuan Yuan, Xue-Feng Sun

Jin-Hua Shan, Department of Gerontology and Geriatrics, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Xiao-Juan Bai, Lu-Lu Han, Department of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

Yuan Yuan, Department of Tumor Research, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Xue-Feng Sun, Department of Kidney, General Hospital of Chinese People's Liberation Army, Beijing 100853, China

ORCID number: Jin-Hua Shan (0000-0002-1130-0784); Xiao-Juan Bai (0000-0003-3890-8391); Lu-Lu Han (0000-0002-8306-4506); Yuan Yuan (0000-0002-9314-3371); Xue-Feng Sun (0000-0002-6569-6737).

**Author contributions:** Shan JH and Bai XJ conceptualized and designed the study; Shan JH and Han LL collected the data; Shan JH and Bai XJ performed analysis and interpretation of the data; Shan JH drafted the manuscript; Bai XJ and Sun XF obtained funding support; Yuan Y provided administrative, technical and material support.

**Supported by the National Basic Research Program of China (973 Program), No. 2007CB507405, No. 2013CB530803 and No. 2013CB530804.**

**Institutional review board statement:** This study was reviewed and approved by the Medical Ethics Committees of the General Hospital of Chinese People's Liberation Army and China Medical University.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Dr. Xiao-Juan Bai, Department of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China. [baixj@sj-hospital.org](mailto:baixj@sj-hospital.org)  
Telephone: +86-24-23516346

Received: April 14, 2017

Peer-review started: April 17, 2017

First decision: May 16, 2017

Revised: May 29, 2017

Accepted: July 12, 2017

Article in press: July 12, 2017

Published online: August 28, 2017

**Abstract****AIM**

To observe changes in gastric biomarker levels with age and effects of *Helicobacter pylori* (*H. pylori*) infection in a healthy population, and explore factors associated with gastric biomarkers.

**METHODS**

Three hundred and ninety-five subjects were selected and underwent physical examinations, biochemical tests, and measurement of serum pepsinogen (PG)

I and II, gastrin-17 (G-17) and *H. pylori* antibody levels. Analyses were made by Student's *t*-test, ANOVA, Pearson's correlation and multiple linear regressions.

### RESULTS

PGII levels were higher in the  $\geq 65$ -years-old age group ( $P < 0.05$ ) and PGI/PGII were lower in the  $\geq 75$ -years-old age group ( $P = 0.035$ ) compared to the 35-44-years-old age group. Levels of low-density lipoprotein cholesterol (LDL-C) were higher ( $P = 0.009$ ) in *H. pylori*-infected subjects that were male. LDL-C levels were higher in 55-74-years-old age group ( $P < 0.05$ ) for *H. pylori*-infected subjects and 45-64-years-old age group ( $P < 0.05$ ) for non-infected subjects compared to 35-44-years-old age group. Hp-IgG level positively correlated with PG I, PG II and G-17 ( $P < 0.001$ ,  $P < 0.001$ ,  $P = 0.006$ ), and negatively correlated with PGI/PGII ( $P < 0.001$ ). Creatinine positively correlated with PG I, PG II and G-17 ( $P < 0.001$ ,  $P < 0.001$ ,  $P < 0.001$ ). Fasting blood glucose (FBG) positively correlated with PG I /PG II and G-17 ( $P < 0.001$ ,  $P = 0.037$ ). Age positively correlated with PGII and G-17 ( $P = 0.005$ ,  $P = 0.026$ ).

### CONCLUSION

PGII levels increased while PGI/PGII declined with age in a healthy population. *H. pylori* infection had an effect on raising LDL-C levels to increase the risk of atherosclerosis in males, especially those of elderly age. Age, *H. pylori* infection, levels of renal function and FBG were associated with levels of pepsinogens and gastrin.

**Key words:** *Helicobacter pylori* antibody; Pepsinogen; Gastrin; Gastric ageing

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Our study showed that in an entire healthy population, levels of serum pepsinogen (PG) II increased while PG I /PG II declined with age. We discovered that *Helicobacter pylori* (*H. pylori*) infection had an effect on raising levels of low-density lipoprotein cholesterol to increase the risk of atherosclerosis in males, especially those who are elderly. We also found that age, *H. pylori* infection, serum levels of renal function indicators and fasting blood glucose (FBG) were associated with levels of serum PGs and gastrin; it was assumed that they may influence the secretory function of gastric mucosa and that abnormal serum levels of FBG and renal function might participate in the occurrence and development of gastric diseases.

Shan JH, Bai XJ, Han LL, Yuan Y, Sun XF. Changes with aging in gastric biomarkers levels and in biochemical factors associated with *Helicobacter pylori* infection in asymptomatic Chinese population. *World J Gastroenterol* 2017; 23(32): 5945-5953 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i32/5945.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23>.

### INTRODUCTION

Ageing of the gastric tract is an early manifestation of overall ageing, and mainly presents as a decline in the secretory function of the gastric mucosa. Histomorphological studies have demonstrated that atrophy of gastric mucosa increases with age<sup>[1-3]</sup>. In addition, studies have also shown that *Helicobacter pylori* (*H. pylori*) infection plays an important role in the progression of gastric mucosa lesions<sup>[4]</sup>. It has been demonstrated that the prevalence of *H. pylori* infection increases with age, and *H. pylori* is closely related with the occurrence and development of peptic ulcers, chronic atrophic gastritis and gastric cancer<sup>[5,6]</sup>.

Serum pepsinogen (PG) levels reflect the number of glands and cells in gastric corpus mucosa. Therefore, they can reflect the secretory function of the gastric mucosa<sup>[7-10]</sup>. It has been reported that the levels of serum PGs are influenced by age, sex, pathophysiologic status of gastric mucosa and *H. pylori* infection<sup>[11]</sup>. Thus, serum PGs are indicators of the functional and morphological status of gastric corpus mucosa, and lower serum levels of PG I or PG I /PG II represent existence and degree of atrophy in gastric corpus mucosa<sup>[12]</sup>.


Serum level of gastrin-17 (G-17) can act as a biomarker that reflects the function and structure of gastric antral mucosa. Combining serum PG and G-17 levels has been shown to provide diagnostic information on gastric mucosa<sup>[13-16]</sup>, and may also reflect the degree of gastric aging. Non-invasive biomarker tests may, therefore, evaluate the secretory function of gastric mucosa and differentiate pathological conditions, such as *H. pylori*-associated gastritis and atrophic gastritis, from the healthy condition by combining tests for PGs, G-17 and *H. pylori*-immunoglobulin G (Hp-IgG)<sup>[17]</sup>.

Previous studies have investigated patients with peptic ulcer, chronic atrophic gastritis and gastric cancer. To date, few studies have observed levels of the aforementioned biomarkers and effects of *H. pylori* infection in a healthy ageing population nor explored the associated factors. In our study, we selected PGs and G-17 as gastric biomarkers and measured their serum levels along with Hp-IgG. The aim of the current study was to observe changes in gastric biomarker levels with age in a healthy Chinese population and effects of *H. pylori* infection on biochemical tests, as well as to explore associated factors which influence the levels of gastric biomarkers.

### MATERIALS AND METHODS

#### Study subjects

This was a cross-sectional study of a healthy population, defined as having no respiratory, cardiovascular,



**Figure 1 Comparison of serum gastric biomarker levels in various age groups.** There was no significant difference in serum levels of PGI and G-17 between each age group with increasing age. In contrast, serum levels of PGII increased with age, and were significantly higher in subjects  $\geq 65$ -years-old compared to 35-44-years-old group. The ratio of PGI/PGII decreased with age, and was significantly lower in subjects  $\geq 75$ -years-old compared to 35-44-years-old group. The "a" denotes comparison with 35-44-years-old age group, <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ . G-17: Gastrin-17; PG I : Pepsinogen I ; PG II : Pepsinogen II .

digestive, neurological, endocrine or urinary system diseases, as well as having absence of neoplastic and chronic infectious diseases and no history of psychiatric disorders. We screened 505 healthy persons out of 1500 volunteers in Shenyang, China between September 2007 and June 2008. The screening included inquiries on medical history, symptoms, smoking, alcohol intake, diet and family history obtained by a questionnaire that was completed by each participant. Physical examinations (*i.e.*, electrocardiogram, chest radiograph, etc.) were carried out along with biochemical tests, including assessments of fasting blood glucose (FBG), blood lipids, liver function, renal function and uric acid levels.

A total of 395 subjects (168 males and 227 females) out of the 505 persons, having a mean age of 59.4 years (range: 37-87 years), were enrolled from November 2010 to May 2011 by the same screening method. Patients with circulatory, respiratory, endocrine, neurological, digestive, urinary diseases and chronic infections or neoplastic diseases, or abnormal physical examinations and test results, as well as those with psychiatric disorders or who were unable to complete instructions and self-evaluations were excluded. Blood samples were obtained and sera were stored (within 2 h of collection) at  $-75^{\circ}\text{C}$  until use for measurement of gastric biomarker levels (within 6 mo).

Informed consent was obtained from each participant. This study was reviewed and approved by the Medical Ethics Committees of General Hospital of Chinese People's Liberation Army and China Medical University.

### Serological assays

Serum PGI and PGII, G-17 and *H. pylori* antibody levels were measured with enzyme-linked immunosorbent assay (ELISA)<sup>[18]</sup> (Biohit Oyj, Laipatie 1, FIN-00880

Helsinki, Finland). All procedures were carried out according to the manufacturer's instructions.

### Study groups

Subjects were divided into five age groups (35-44, 45-54, 55-64, 65-74 and  $\geq 75$  years). Hp-IgG-positive or -negative groups (Hp-IgG-positive defined as serum Hp-IgG  $\geq 35$  EIU)<sup>[19]</sup> were also established.

### Statistical analysis

Serum biomarker levels and serum biochemical tests were analyzed in *H. pylori*-positive and *H. pylori*-negative patients, separately in male and female subjects, by Student's *t*-test. Levels of serum gastric biomarkers among age groups and levels of serum gastric biomarkers and biochemical tests among age groups divided by *H. pylori* infection status were compared by ANOVA, and multiple comparisons were carried out by the Bonferroni method (homogeneity of variance) or Tamhane method (heterogeneity of variance). Relationships among serum gastric biomarker levels, age and biochemical tests were analyzed by Pearson's correlation coefficient matrix. Serum gastric biomarkers as dependent variables and other related factors as independent variables were analyzed by multiple linear regression analysis with stepwise method and multiple-collinearity. For all statistical analyses, we used SPSS V.17.0, and a two-sided *P* value of  $< 0.05$  was considered statistically significant.

## RESULTS

### Comparison of serum gastric biomarker levels in various age groups

There was no significant difference in serum levels of PGI and G-17 between each age group with increasing age. In contrast, serum levels of PGII increased with age, and were significantly higher in subjects  $\geq 65$ -years-old compared to the 35-44-years-old group ( $P = 0.024$ ,  $P = 0.004$ ). The ratio of PGI / PGII decreased with age and was significantly lower in subjects  $\geq 75$ -years-old compared to those in the 35-44-years-old group ( $P = 0.035$ ) (Table 1 and Figure 1).

### Comparison of serum gastric biomarker levels by *H. pylori* infection status

Compared to non-infected subjects, serum levels of PGI, PGII and G-17 were significantly higher ( $P < 0.001$ ,  $P < 0.001$ ,  $P = 0.025$ ), while the ratio of PGI / PGII was significantly lower ( $P < 0.001$ ), in the *H. pylori*-infected subjects (Figure 2).


### Comparison of serum biochemical tests between *H. pylori* infection statuses by sex

There was no significant difference in serum levels of biochemical tests between *H. pylori*-infected and non-infected female subjects. In males, levels of low-density lipoprotein cholesterol (LDL-C) were higher ( $P$

**Table 1 Comparison of serum gastric biomarker levels in various age groups**

	35-44 yr, n = 58	45-54 yr, n = 84	55-64 yr, n = 117	65-74 yr, n = 76	≥ 75 yr, n = 60	F	P value
PG I, µg/L	92.98 ± 5.16	98.47 ± 4.15	98.65 ± 3.66	108.56 ± 8.01	117.04 ± 8.30	2.326	0.056
PG II, µg/L	9.65 ± 0.73	12.26 ± 0.91	12.43 ± 0.76	14.23 ± 1.17 <sup>1a</sup>	15.33 ± 1.25 <sup>1b</sup>	3.915	0.004
PG I /PG II	10.94 ± 0.44	9.89 ± 0.40	9.67 ± 0.36	9.29 ± 0.61	8.71 ± 0.52 <sup>1a</sup>	2.407	0.049
G-17, pmol/L	2.93 ± 0.55	5.10 ± 1.29	5.75 ± 1.49	9.93 ± 3.00	10.03 ± 3.18	1.950	0.101

Data are presented as mean ± SD. <sup>1</sup>Comparison with the 35-44-years-old group, <sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01. G-17: Gastrin-17; PG I : Pepsinogen I ; PG II: Pepsinogen II.



**Figure 2 Comparison of serum gastric biomarker levels by *Helicobacter pylori* infection status.** Compared to non-infected subjects, serum levels of PG I, PG II and G-17 were significantly higher, while the ratio of PG I /PG II was significantly lower in *Helicobacter pylori*-infected subjects. <sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01. G-17: Gastrin-17; PG I : Pepsinogen I ; PG II: Pepsinogen II.

= 0.009) in *H. pylori*-infected subjects compared to non-infected subjects (Table 2).


**Comparison of serum gastric biomarker levels and biochemical tests in various age groups by *H. pylori* infection status**

There was no significant difference in serum levels of gastric biomarkers between each age group with increasing age in *H. pylori*-infected subjects. In non-infected subjects, levels of serum PG II increased with age and were significantly higher in subjects ≥ 75-years-old compared to subjects between 35- and 54-years-old (P = 0.007, P = 0.004).

In *H. pylori*-infected subjects, serum levels of total cholesterol (P = 0.002, P = 0.001) and LDL-C (P = 0.016, P = 0.002) were significantly higher in subjects between 55- and 74-years-old compared to those in the 35-44-years-old age group. In non-infected subjects, serum levels of total cholesterol (P = 0.023, P = 0.035) and LDL-C (P = 0.015, P = 0.006) were significantly higher in subjects between 45- and 64-years-old compared to those in the 35-44-years-old group (Table 3 and Figure 3).

**Correlation analysis among serum gastric biomarker levels, age and biochemical tests**

Age positively correlated with serum levels of Hp-IgG, PG I, PG II and G-17 (P = 0.038, P = 0.001, P < 0.001, P = 0.005) and negatively correlated with ratio of PG I



**Figure 3 Comparison of serum cholesterol levels in various age groups by *Helicobacter pylori* infection status.** In *H. pylori*-infected subjects, serum levels of TC and LDL were significantly higher in subjects between 55- and 74-years-old compared to those in the 35-44-years-old age group. In non-infected subjects, serum levels of TC and LDL were significantly higher in subjects between 45- and 64-years-old compared to those in the 35-44-years-old age group. The “a” denotes comparison with the 35-44-years-old age group and the “b” denotes comparison with the 45-54-years-old age group, <sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01. *H. pylori*: *Helicobacter pylori*; LDL-C: Low-density lipoprotein cholesterol; TC: Total cholesterol.

/PG II (P = 0.002). Levels of serum Hp-IgG positively correlated with serum levels of PG I, PG II and G-17 (P < 0.001, P < 0.001, P = 0.038) and negatively correlated with ratio of PG I /PG II (P < 0.001).

Levels of serum PG I positively correlated with serum levels of uric acid, creatinine and cystatin-C (P < 0.001, P < 0.001, P < 0.001). Levels of serum PG II positively correlated with serum levels of creatinine and cystatin-C (P < 0.001, P < 0.001). Levels of serum G-17 positively correlated with serum levels of FBG, creatinine and cystatin-C (P = 0.018, P = 0.011, P = 0.037).

Levels of serum Hp-IgG were strongly associated with serum levels of PG II and PG I /PG II (r = 0.592, P < 0.001; r = -0.587, P < 0.001), and levels of serum PG II were strongly associated with serum levels of PGI and PG I /PG II (r = 0.682, P < 0.001; r = -0.588, P < 0.001)(Table 4).

**Analysis of factors associated with serum levels of gastric biomarkers**

With serum PGI as a dependent variable, serum levels of creatinine, Hp-IgG and FBG positively correlated with levels of serum PG I (P < 0.001, P < 0.001,

**Table 2** Comparison of serum biochemical tests between *Helicobacter pylori* infection statuses by sex

	Male			Female		
	Hp-IgG (+), n = 81	Hp-IgG (-), n = 87	P value	Hp-IgG (+), n = 104	Hp-IgG (-), n = 123	P value
TG, mmol/L	1.33 ± 0.11	1.30 ± 0.17	0.875	1.24 ± 0.06	1.26 ± 0.06	0.767
TC, mmol/L	5.07 ± 0.11	4.80 ± 0.09	0.052	5.16 ± 0.09	5.42 ± 0.09	0.050
HDL-C, mmol/L	1.31 ± 0.04	1.35 ± 0.03	0.381	1.52 ± 0.03	1.54 ± 0.03	0.575
LDL-C, mmol/L	3.30 ± 0.10	2.99 ± 0.07	0.009	3.26 ± 0.09	3.48 ± 0.08	0.071
FBG, mmol/L	5.45 ± 0.09	5.26 ± 0.06	0.073	5.29 ± 0.06	5.27 ± 0.09	0.857
Cr, μmol/L	72.58 ± 1.76	73.26 ± 1.40	0.760	60.66 ± 2.59	55.34 ± 0.89	0.054
Cys-C, mg/L	0.93 ± 0.02	0.91 ± 0.02	0.520	0.88 ± 0.03	0.81 ± 0.02	0.059
UA, μmol/L	339.05 ± 8.19	337.48 ± 9.04	0.898	265.13 ± 6.19	273.22 ± 5.30	0.319

Data are presented as mean ± SD. *H. pylori*-IgG (+) is defined as *H. pylori*-IgG ≥ 35 EIU. Cr: Creatinine; Cys-C: Cystatin-C; FBG: Fasting blood glucose; HDL-C: High-density lipoprotein cholesterol; Hp-IgG: Helicobacter pylori-immunoglobulin G; LDL-C: Low-density lipoprotein cholesterol; TC: Total cholesterol; TG: Triglycerides; UA: Uric acid; *H. pylori*: *Helicobacter pylori*.

**Table 3** Comparison of serum gastric biomarker levels and biochemical tests in various age groups by *Helicobacter pylori* infection status

	35-44 yr n1 = 21 n2 = 37	45-54 yr n1 = 39 n2 = 45	55-64 yr n1 = 57 n2 = 60	65-74 yr n1 = 36 n2 = 40	≥ 75 yr n1 = 33 n2 = 27	F	P value
PGI, μg/L							
Hp-IgG (+)	89.43 ± 7.46	100.03 ± 6.45	90.25 ± 5.10	92.61 ± 12.23	94.95 ± 13.47	0.824	0.920
Hp-IgG (-)	83.6 ± 6.47	81.28 ± 3.89	83.96 ± 5.04	96.67 ± 10.31	105.49 ± 8.08	1.730	0.143
PGII, μg/L							
Hp-IgG (+)	14.68 ± 1.08	18.45 ± 1.34	17.47 ± 1.16	19.52 ± 1.46	19.51 ± 1.91	1.393	0.260
Hp-IgG (-)	6.80 ± 0.58	6.89 ± 0.41	7.64 ± 0.46	9.46 ± 1.42	10.23 ± 0.76 <sup>1b2b</sup>	1.115	0.011
PGI/PGII							
Hp-IgG (+)	7.92 ± 0.53	7.17 ± 0.39	7.03 ± 0.38	6.65 ± 0.58	6.97 ± 0.52	0.662	0.616
Hp-IgG (-)	12.66 ± 0.41	12.25 ± 0.42	12.18 ± 0.39	11.68 ± 0.89	10.85 ± 0.80	1.163	0.353
G-17, pmol/L							
Hp-IgG (+)	4.11 ± 0.74	9.81 ± 2.58	8.18 ± 2.17	7.16 ± 0.95	13.7 ± 4.79	1.258	0.285
Hp-IgG (-)	2.26 ± 0.73	1.02 ± 0.26	3.44 ± 2.03	12.43 ± 5.65	5.54 ± 3.90	2.254	0.066
TC, mmol/L							
Hp-IgG (+)	4.42 ± 0.14	4.96 ± 0.14	5.30 ± 0.11 <sup>1b</sup>	5.51 ± 0.19 <sup>1b</sup>	5.00 ± 0.15	6.604	< 0.001
Hp-IgG (-)	4.77 ± 0.10	5.41 ± 0.17 <sup>1a</sup>	5.35 ± 0.13 <sup>1a</sup>	5.18 ± 0.16	4.98 ± 0.14	2.709	0.031
LDL-C, mmol/L							
Hp-IgG (+)	2.71 ± 0.14	3.10 ± 0.12	3.40 ± 0.11 <sup>1a</sup>	3.60 ± 0.17 <sup>1b2a</sup>	3.17 ± 0.14	7.291	< 0.001
Hp-IgG (-)	2.89 ± 0.09	3.47 ± 0.15 <sup>1a</sup>	3.48 ± 0.11 <sup>1b</sup>	3.33 ± 0.13	3.08 ± 0.13	3.544	0.008
FBG, mmol/L							
Hp-IgG (+)	5.25 ± 0.08	5.22 ± 0.13	5.38 ± 0.12	5.46 ± 0.12	5.44 ± 0.08	0.791	0.532
Hp-IgG (-)	5.01 ± 0.06	5.21 ± 0.08	5.29 ± 0.08	5.34 ± 0.08	5.39 ± 0.34	1.186	0.318
Cr, μmol/L							
Hp-IgG (+)	56.95 ± 2.57	60.38 ± 2.35	63.79 ± 1.71	63.61 ± 3.04	81.4 ± 7.24 <sup>1a</sup>	4.974	0.001
Hp-IgG (-)	59.19 ± 2.05	62.78 ± 1.95	61.20 ± 1.67	63.53 ± 2.29	73.19 ± 3.40 <sup>1b2a3b</sup>	4.174	0.003
Cys-C, mg/dL							
Hp-IgG (+)	0.69 ± 0.02	0.78 ± 0.02 <sup>1a</sup>	0.84 ± 0.02 <sup>1b</sup>	0.97 ± 0.03 <sup>1b2b3a</sup>	1.19 ± 0.07 <sup>1b2b3b</sup>	19.952	< 0.001
Hp-IgG (-)	0.71 ± 0.02	0.78 ± 0.02	0.83 ± 0.02 <sup>1b</sup>	0.93 ± 0.03 <sup>1b2b</sup>	1.14 ± 0.04 <sup>1b2b3b4b</sup>	28.435	< 0.001

Data are presented as mean ± SD. Hp-IgG (+) is defined as Hp-IgG ≥ 35 EIU. n1: number in the Hp-IgG (+) group; n2: number in the Hp-IgG(-) group. <sup>1</sup>35-44-years-old group, <sup>2</sup>45-54-years-old group, <sup>3</sup>55-64-years-old group, <sup>4</sup>65-74-years-old group, <sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01. Cr: Creatinine; Cys-C: Cystatin-C; FBG: Fasting blood glucose; G-17: Gastrin-17; Hp-IgG: *Helicobacter pylori*-immunoglobulin G; LDL-C: Low-density lipoprotein cholesterol; PG I: Pepsinogen I; PG II: Pepsinogen II; TC: Total cholesterol.

*P* = 0.037), while serum levels of G-17 negatively correlated with levels of serum PG I (*P* < 0.001). With serum PGII as a dependent variable, serum levels of creatinine, Hp-IgG and age positively correlated with levels of serum PGII (*P* = 0.006, *P* < 0.001, *P* = 0.007). With PG I/PGII as a dependent variable, serum levels of FBG positively correlated with PGI/PGII (*P* < 0.001), while serum levels of Hp-IgG, G-17 and age negatively correlated with PG I/PGII (*P* < 0.001, *P* < 0.001, *P* = 0.024). With serum G-17 as a dependent variable,

age and serum levels of creatinine, Hp-IgG and FBG positively correlated with levels of serum G-17 (*P* = 0.032, *P* < 0.001, *P* = 0.037, *P* = 0.045), while serum levels of PGI and uric acid negatively correlated with levels of serum G-17 (*P* < 0.001, *P* = 0.009)(Table 5).

## DISCUSSION

A European gastric biomarkers test<sup>[17]</sup> has been developed to measure serum PG and G-17 levels, and

Table 4 Correlation matrix among serum gastric biomarker levels, age and biochemical tests

Age	PG I	PG II	PG I / II	G-17	Hp-IgG	TG	TC	HDL-C	LDL-C	FBG	UA	Cr	Cys-C	BMI
Age	1	0.161 <sup>b</sup>	0.215 <sup>b</sup>	-0.155 <sup>b</sup>	0.140 <sup>b</sup>	-0.009	0.108 <sup>a</sup>	0.010	0.136 <sup>b</sup>	0.145 <sup>b</sup>	0.148 <sup>b</sup>	0.265 <sup>b</sup>	0.548 <sup>b</sup>	-0.016
PG I	0.001	1.000	0.000	0.038	0.038	0.854	0.033	0.844	0.007	0.004	0.003	0.000	0.000	0.781
PG II	0.000	1.000	0.682 <sup>b</sup>	0.047	0.260 <sup>b</sup>	-0.014	-0.066	-0.051	-0.023	0.056	0.188 <sup>b</sup>	0.301 <sup>b</sup>	0.355 <sup>b</sup>	0.011
PG I / II	0.000	0.000	1.000	0.357	0.000	0.788	0.188	0.308	0.654	0.266	0.000	0.000	0.000	0.843
G-17	0.003	0.003	0.000	1.000	0.592 <sup>b</sup>	-0.029	-0.062	-0.075	-0.019	-0.005	0.077	0.000	0.000	0.006
Hp- IgG	0.038	0.038	0.000	1.000	1.000	0.571	0.216	0.135	0.705	0.915	0.124	0.000	0.000	0.913
TG	0.000	0.000	0.000	0.000	1.000	1.000	0.032	0.040	0.027	0.074	0.080	-0.019	-0.060	0.003
TC	0.000	0.000	0.000	0.000	0.000	1.000	0.532	0.427	0.590	0.140	0.112	0.712	0.234	0.961
HDL-C	0.038	0.038	0.000	0.000	0.000	0.000	-0.020	-0.068	-0.016	0.119 <sup>a</sup>	-0.062	0.129 <sup>a</sup>	0.105 <sup>a</sup>	-0.023
LDL-C	0.038	0.038	0.000	0.000	0.000	0.000	0.695	0.177	0.749	0.018	0.219	0.011	0.037	0.690
FBG	0.000	0.000	0.000	0.000	0.000	0.000	-0.025	-0.062	-0.004	0.057	0.009	0.058	0.095	0.006
UA	0.000	0.000	0.000	0.000	0.000	0.000	0.618	0.220	0.938	0.257	0.865	0.250	0.059	0.919
Cr	0.000	0.000	0.000	0.000	0.000	0.000	0.278 <sup>b</sup>	-0.327 <sup>b</sup>	0.145 <sup>b</sup>	0.166 <sup>b</sup>	0.156 <sup>b</sup>	0.059	0.068	0.048
Cys-C	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.295 <sup>b</sup>	0.896 <sup>b</sup>	0.001	0.002	0.243	0.176	0.402
BMI	0.000	0.000	0.000	0.000	0.000	0.000	1.000	1.000	1.000	0.064	0.000	-0.032	-0.039	0.111
										0.074	0.074	0.530	0.442	0.053
										0.003	0.003	-0.176 <sup>b</sup>	-0.164 <sup>b</sup>	0.017
										1.000	1.000	0.000	0.001	0.762
										1.000	1.000	10.000	0.022	0.085
										1.000	1.000	0.142	0.664	0.138
										1.000	1.000	0.111 <sup>a</sup>	0.086	0.034
										1.000	1.000	0.018	0.086	0.558
										1.000	1.000	0.465 <sup>b</sup>	0.403 <sup>b</sup>	-0.003
										1.000	1.000	0.000	0.000	0.961
										1.000	1.000	0.000	0.706 <sup>b</sup>	-0.010
										1.000	1.000	1.000	0.000	0.858
										1.000	1.000	1.000	1.000	-0.026
										1.000	1.000	1.000	1.000	0.648
										1.000	1.000	1.000	1.000	1.000

<sup>a</sup>  $p < 0.05$ , <sup>b</sup>  $p < 0.01$ . BMI: Body mass index; Cr: Creatinine; Cys-C: Cystatin-C; FBG: Fasting blood glucose; G-17: Gastrin-17; Hp-IgG: *Helicobacter pylori*-immunoglobulin G; LDL-C: Low-density lipoprotein cholesterol; PG I: Pepsinogen I; PG II: Pepsinogen II; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; TG: Triglyceride; UA: Uric acid.

Hp-IgG antibodies by ELISA technique. Compared to endoscopic biopsy findings, the test classified the subjects into groups with "healthy" or "diseased" gastric mucosa with 94% accuracy, 95% sensitivity and 93% specificity. Compared to endoscopic histological findings, the accuracy of the biomarkers test in diagnosing atrophic gastritis was 87%, with a sensitivity of 40% and a specificity of 94%. Combined testing of Hp-IgG, PG and G-17 levels is of great clinical significance for general assessment of gastric mucosa secretion.

It has been previously shown that levels of serum PG I decreased with age. Levels of serum PGII increased with age, but declined in participants aged over 60. Ratio of PG I/PGII decreased with age, but it increased after age 60<sup>[20]</sup>. It has also been observed that levels of PGI and PGII increased with age. In a healthy population, levels of PG I and PGII varied amongst age groups, and the average PG level was highest in the senile group<sup>[21]</sup>.

Our study showed that in the entire healthy study population, levels of serum PG II increased with age, while the ratio of PG I /PGII decreased with age. The correlation between age and PG II is stronger and more significant than that of PG I ; possibly, the distribution of PG II-secreting cells is more extensive, and this could

Table 5 Factors associated with serum levels of gastric biomarkers

Dependent variable	Associated factors	Non-standard coefficient		Standard coefficient	P value
		B	SE	$\beta$	
PGI	Constant	50.347	200.845		0.798
	Cr	0.712	0.138	0.273	0.000
	Hp-IgG	0.334	0.066	0.263	0.000
	G-17	-0.647	0.138	-0.247	0.000
	FBG	70.859	30.744	0.110	0.037
PGII	Constant	-10.657	20.078		0.426
	Hp-IgG	0.120	0.010	0.556	0.000
	Cr	0.058	0.021	0.131	0.006
	Age	0.089	0.033	0.129	0.007
PGI /PGII	Constant	90.251	10.461		0.000
	Hp-IgG	-0.054	0.004	-0.520	0.000
	G-17	-0.075	0.009	-0.349	0.000
	FBG	10.037	0.255	0.177	0.000
	Age	-0.033	0.015	-0.101	0.024
G-17	Constant	-140.817	80.992		0.100
	Age	0.192	0.089	0.1240	0.032
	PGI	-0.103	0.022	-0.269	0.000
	Cr	0.228	0.063	0.228	0.000
	Hp-IgG	0.058	0.027	0.119	0.037
	UA	-0.042	0.016	-0.160	0.009
	FBG	30.054	10.520	0.112	0.045

Cr: Creatinine; FBG: Fasting blood glucose; G-17: Gastrin-17; Hp-IgG: *Helicobacter pylori*-immunoglobulin G; PG I : Pepsinogen I ; PG II: Pepsinogen II; UA: Uric acid.

be one of the reasons to explain this finding. Since the ratio of PG I /PG II reflects the degree of atrophy in gastric mucosa, the current study indicated that atrophy of gastric mucosa occurred and developed with increasing age in a non-invasive serological method.

It has been suggested that serum levels of PGI and PGII significantly correlated with age in *H. pylori*-positive subjects. Increased PG I and PG II levels associated with age in a healthy population were caused by increased rates of *H. pylori* infection. Levels of PG I and PG II were dependent on the presence of *H. pylori* infection<sup>[22]</sup>. It was suggested that serum levels of G-17, PGI and PGII increased in subjects with *H. pylori* infection, especially PG II, while the ratio of PG I /PG II decreased.

Hypergastrinemia and hyperpepsinogenemia may be secondary to *H. pylori* infection<sup>[23,24]</sup>. The results of the current study on the effects of *H. pylori* infection on serum gastric biomarker levels were consistent with those of previous studies, and it was suggested that *H. pylori* infection had a closer correlation with PG II than with PG I and may influence the levels of PG II more.

It has been shown that *H. pylori* infection was independently associated with elevated LDL-C levels and contributed to the atherosclerotic process<sup>[25]</sup>. The current study showed the difference on levels of serum LDL-C between *H. pylori*-infected and non-infected male subjects, which suggested an effect of *H. pylori* infection on raising levels of LDL-C in males. Meanwhile, the highest level of LDL-C was found in the middle-aged group (45-64 years) in non-infected subjects, while in *H. pylori*-infected subjects it was found in the elderly group (55-74 years). Increased

LDL-C level is a risk factor for the development of atherosclerosis, and the current study indicated that Hp infection may increase the risks of atherosclerosis in males, especially those of elderly age.

It has been reported that renal function status may influence levels of serum PG and gastrin. Levels of serum PG and gastrin were found to be increased in patients with renal function insufficiency. This may have been due to reduced renal clearance of PG and gastrin<sup>[26,27]</sup>. There have been few studies investigating the relationship between renal function and serum PG and gastrin in a healthy population. The current study showed that age and serum levels of Hp-IgG, creatinine and FBG were the main factors associated with levels of serum PG and G-17. Since different levels of PG and G-17 represent different pathophysiological status of gastric mucosa, it was assumed that age, *H. pylori* infection, and serum levels of FBG and markers of renal function may influence the secretory function of gastric mucosa, and that abnormal serum levels of FBG and renal function might participate in the occurrence and development of gastric diseases.

In summary, the current study observed changes in gastric biomarker levels with age and effects of *H. pylori* infection in a healthy Chinese population, and explored factors associated with gastric biomarkers. Our data provide a theoretical basis for the recognition of gastric aging and its related diseases, which is of important clinical significance. However, there are some limitations in the study. Firstly, the sample size was relatively small and may, therefore, not represent the whole healthy population. Secondly, we found the effects of *H. pylori* infection and the correlation between gastric biomarkers and other associated factors, but the

mechanisms are not clear. More studies are needed to illustrate the mechanisms in the future.

## COMMENTS

### Background

Combined testing of *Helicobacter pylori* (*H. pylori*)-immunoglobulin G (Hp-IgG), pepsinogen (PG) and G-17 levels is of great clinical significance for general assessment of gastric mucosa secretion, and may also reflect the degree of gastric aging. Previous studies have investigated patients with peptic ulcer, chronic atrophic gastritis and gastric cancer. To date, few studies have observed levels of the gastric biomarkers and effects of *H. pylori* infection in a healthy ageing population nor explored the associated factors.

### Research frontiers

Non-invasive biomarker tests may evaluate the secretory function of gastric mucosa, and distinguish pathological conditions, such as atrophic gastritis, from the healthy condition by combining tests for PGs, G-17 and Hp-IgG. Lower serum levels of PGI or PG I /PGII represent existence and degree of atrophy in gastric corpus mucosa. Studies have indicated that serum levels of PGs and G-17 are related to *H. pylori* infection and age, and could be significantly influenced by *H. pylori* infection. Furthermore, it has been shown that *H. pylori* infection was independently associated with elevated low-density lipoprotein cholesterol (LDL-C) levels and contributed to the atherosclerotic process.

### Innovations and breakthroughs

The current study observed changes in gastric biomarker levels with age and effects of *H. pylori* infection in a healthy Chinese population, and explored factors associated with gastric biomarkers. This study showed that in the entire healthy study population, levels of serum PGII increased while PGI/PGII declined with age, which indicated that atrophy of gastric mucosa occurred and developed with increasing age, observed via a non-invasive serological method. Meanwhile, we discovered that *H. pylori* infection had an effect on raising levels of LDL-C to increase the risk of atherosclerosis in males, especially those of elderly age. Moreover, it is suggested that age, *H. pylori* infection, serum levels of renal function and fasting blood glucose (FBG) were associated with levels of serum PGs and gastrin.

### Applications

In this study, the authors' discovered that *H. pylori* infection had an effect on raising levels of LDL-C to increase the risk of atherosclerosis in males, especially those who were elderly, which indicated that *H. pylori* infection should be afforded a more important status and given active treatment in elderly males to prevent atherosclerotic diseases. This study suggested that age, *H. pylori* infection, serum levels of renal function and FBG were associated with levels of serum PGs and gastrin. It was assumed that serum levels of renal function and FBG may influence the secretory function of gastric mucosa, and abnormal serum levels of FBG and renal function might participate in the occurrence and development of gastric diseases.

### Terminology

*H. pylori*: A curved Gram-negative bacillus which is found in gastric mucosa; *H. pylori* is closely related with multiple gastric diseases, such as peptic ulcers, chronic atrophic gastritis and gastric cancer. PG: A precursor of pepsin which is mainly secreted by cells in the gastric corpus and can be divided into two groups, PG I and PGII; serum PG levels reflect the number of glands and cells, as well as the secretory function in gastric corpus mucosa. G-17: A hormone which is mainly secreted by G cells in gastric antrum and plays multiple physiological roles; serum level of G-17 reflects the number of cells and the secretory function in gastric antral mucosa.

### Peer-review

The authors have carried out a detailed study of biomarkers and *H. pylori* infection in a large cohort of patients. The manuscript is detailed, the study well carried out and the data is comprehensive and complex.

## REFERENCES

- Kang JM**, Kim N, Kim JH, Oh E, Lee BY, Lee BH, Shin CM, Park JH, Lee MK, Nam RH, Lee HE, Lee HS, Kim JS, Jung HC, Song IS. Effect of aging on gastric mucosal defense mechanisms: ROS, apoptosis, angiogenesis, and sensory neurons. *Am J Physiol Gastrointest Liver Physiol* 2010; **299**: G1147-G1153 [PMID: 20724528 DOI: 10.1152/ajpgi.00218.2010]
- Park KS**. [Aging and digestive diseases: at the view of the functional change of gastrointestinal tract]. *Korean J Gastroenterol* 2011; **58**: 3-8 [PMID: 21778797]
- Salles N**. Basic mechanisms of the aging gastrointestinal tract. *Dig Dis* 2007; **25**: 112-117 [PMID: 17468545 DOI: 10.1159/000099474]
- Malfirtheiner P**, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007; **56**: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
- Massarrat S**, Haj-Sheykholeslami A, Mohamadkhani A, Zendeheh N, Rakhshani N, Stolte M, Mirzaei M, Saliminejad M, Saeidi S, Shahidi M. Precancerous conditions after *H. pylori* eradication: a randomized double blind study in first degree relatives of gastric cancer patients. *Arch Iran Med* 2012; **15**: 664-669 [PMID: 23102241]
- Chen TS**, Lee YC, Li FY, Chang FY. Smoking and hyperpepsinogenemia are associated with increased risk for duodenal ulcer in *Helicobacter pylori*-infected patients. *J Clin Gastroenterol* 2005; **39**: 699-703 [PMID: 16082280]
- Kiyohira K**, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K. Serum pepsinogen concentration as a marker of *Helicobacter pylori* infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. *J Gastroenterol* 2003; **38**: 332-338 [PMID: 12743772 DOI: 10.1007/s005350300060]
- Derakhshan MH**, El-Omar E, Oien K, Gillen D, Fyfe V, Crabtree JE, McColl KE. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with *Helicobacter pylori*. *J Clin Pathol* 2006; **59**: 1293-1299 [PMID: 16644877 DOI: 10.1136/jcp.2005.036111]
- di Mario F**, Cavallaro LG. Non-invasive tests in gastric diseases. *Dig Liver Dis* 2008; **40**: 523-530 [PMID: 18439884 DOI: 10.1016/j.dld.2008.02.028]
- Sun LP**, Gong YH, Wang L, Gong W, Yuan Y. Follow-up study on a high risk population of gastric cancer in north China by serum pepsinogen assay. *J Dig Dis* 2008; **9**: 20-26 [PMID: 18251790 DOI: 10.1111/j.1443-9573.2007.00321.x]
- Sun LP**, Gong YH, Wang L, Yuan Y. Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China. *World J Gastroenterol* 2007; **13**: 6562-6567 [PMID: 18161928 DOI: 10.3748/wjg.13.6562]
- Iijima K**, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, Shimosegawa T. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. *World J Gastroenterol* 2009; **15**: 853-859 [PMID: 19230047 DOI: 10.3748/wjg.15.853]
- Broutet N**, Plebani M, Sakarovitch C, Sipponen P, Mégraud F; Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. *Br J Cancer* 2003; **88**: 1239-1247 [PMID: 12698190 DOI: 10.1038/sj.bjc.6600877]
- Kikuchi R**, Abe Y, Iijima K, Koike T, Ara N, Uno K, Asanuma K, Asano N, Imatani A, Shimosegawa T. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. *Tohoku J Exp Med* 2011; **223**: 35-44 [PMID: 21222340]
- Cao Q**, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and *Helicobacter pylori* immunoglobulin G antibodies. *J Dig Dis* 2007; **8**: 15-22 [PMID: 17261130 DOI: 10.1111/j.1443-9573.2007.00271.x]

- 16 **Haj-Sheykholeslami A**, Rakhshani N, Amirzargar A, Rafiee R, Shahidi SM, Nikbin B, Khosravi F, Massarrat S. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. *Clin Gastroenterol Hepatol* 2008; **6**: 174-179 [PMID: 18237867 DOI: 10.1016/j.cgh.2007.11.016]
- 17 **Storskrubb T**, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agréus L. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. *Scand J Gastroenterol* 2008; **43**: 1448-1455 [PMID: 18663663 DOI: 10.1080/00365520802273025]
- 18 **González CA**, Megraud F, Buissonniere A, Lujan Barroso L, Agudo A, Duell EJ, Boutron-Ruault MC, Clavel-Chapelon F, Palli D, Krogh V, Mattiello A, Tumino R, Sacerdote C, Quirós JR, Sanchez-Cantalejo E, Navarro C, Barricarte A, Dorronsoro M, Khaw KT, Wareham N, Allen NE, Tsilidis KK, Bas Bueno-de-Mesquita H, Jeurink SM, Numans ME, Peeters PH, Lagiou P, Valanou E, Trichopoulou A, Kaaks R, Lukanova-McGregor A, Bergman MM, Boeing H, Manjer J, Lindkvist B, Stenling R, Hallmans G, Mortensen LM, Overvad K, Olsen A, Tjønneland A, Bakken K, Dumeaux V, Lund E, Jenab M, Romieu I, Michaud D, Mouw T, Carneiro F, Fenge C, Riboli E. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. *Ann Oncol* 2012; **23**: 1320-1324 [PMID: 21917738 DOI: 10.1093/annonc/mdr384]
- 19 **He CY**, Sun LP, Gong YH, Xu Q, Dong NN, Yuan Y. Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. *J Gastroenterol Hepatol* 2011; **26**: 1039-1046 [PMID: 21303408 DOI: 10.1111/j.1440-1746.2011.06692.x]
- 20 **Rollan A**, Ferreccio C, Gederlini A, Serrano C, Torres J, Harris P. Non-invasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. *World J Gastroenterol* 2006; **12**: 7172-7178 [PMID: 17131482 DOI: 10.3748/wjg.v12.i44.7172]
- 21 **Miki K**, Fujishiro M, Kodashima S, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. *Dig Endosc* 2009; **21**: 78-81 [PMID: 19691778 DOI: 10.1111/j.1443-1661.2009.00839.x]
- 22 **Kim HY**, Kim N, Kang JM, Park YS, Lee DH, Kim YR, Kim JS, Jung HC, Song IS. Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea. *Eur J Gastroenterol Hepatol* 2009; **21**: 606-612 [PMID: 19293719 DOI: 10.1097/MEG.0b013e3283086757]
- 23 **Leung WK**, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ; Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. *Lancet Oncol* 2008; **9**: 279-287 [PMID: 18308253 DOI: 10.1016/S1470-2045(08)70072-X]
- 24 **Massarrat S**, Haj-Sheykholeslami A, Mohamadkhani A, Zendeheel N, Aliasgari A, Rakhshani N, Stolte M, Shahidi SM. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after *H. pylori* eradication. *Biomed Res Int* 2014; **2014**: 481607 [PMID: 25028655 DOI: 10.1155/2014/481607]
- 25 **Gong Y**, Wei W, Jingwei L, Nannan D, Yuan Y. Helicobacter pylori Infection Status Correlates with Serum Parameter Levels Responding to Multi-organ Functions. *Dig Dis Sci* 2015; **60**: 1748-1754 [PMID: 25599961 DOI: 10.1007/s10620-015-3522-2]
- 26 **Furgala A**, Blaut-Kadzielska U, Stojakowska M, Dobrek Ł, Mazur M, Machowska A, Thor PJ. Gastric dysfunction in dialysed patients with chronic renal failure. *Folia Med Cracov* 2012; **52**: 39-55 [PMID: 23697214]
- 27 **Gong Y**, Wang W, Li Y, Yuan Y. Serum Indicators Reflecting Gastric Function May Also Correlate with Other Extragastric Diseases. *Gastroenterol Res Pract* 2015; **2015**: 867495 [PMID: 26339238 DOI: 10.1155/2015/867495]

**P- Reviewer:** Bramhall S, Lombardo L, Yamaoka Y **S- Editor:** Qi Y  
**L- Editor:** Filipodia **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

